| P50 | author | Jean-Louis Montastruc | Q33102518 |
| P2093 | author name string | Pierre Petit | |
| | Jean-Luc Faillie | |
| | Dominique Hillaire-Buys | |
| P2860 | cites work | Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis | Q27002540 |
| | Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis | Q27311601 |
| | Diabetes and cancer: a consensus report. | Q27686977 |
| | Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 |
| | Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells | Q28345289 |
| | Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 |
| | PROactive study | Q82968684 |
| | Stay vigilant: a glitazone (pioglitazone) can hide a glitazar! | Q84108503 |
| | Meta-analysis confirms raised risk of bladder cancer from pioglitazone | Q84522675 |
| | Evaluation of vitamin B12 effects on DNA damage induced by pioglitazone | Q84568131 |
| | PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma | Q33235601 |
| | Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive | Q33425406 |
| | Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats | Q33800079 |
| | Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies | Q34324440 |
| | The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients | Q34329426 |
| | Thiazolidinediones | Q34346862 |
| | Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 |
| | Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 |
| | Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 |
| | Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 |
| | Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials | Q34781949 |
| | Glycemic control in type 2 diabetes: time for an evidence-based about-face? | Q34976880 |
| | Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting | Q35043204 |
| | Diabetes and risk of bladder cancer: evidence from a case-control study in New England | Q35051024 |
| | Pioglitazone and bladder cancer: a population-based study of Taiwanese. | Q35688201 |
| | Effect of rifampicin on the pharmacokinetics of pioglitazone | Q35827325 |
| | The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 |
| | Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study | Q36013549 |
| | Effects of PPARgamma and combined agonists on the urinary tract of rats and other species | Q36210174 |
| | Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis | Q36247512 |
| | DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents | Q36499766 |
| | Pioglitazone and bladder cancer: a propensity score matched cohort study | Q36562522 |
| | Diabetes mellitus and risk of bladder cancer: a meta-analysis | Q36615062 |
| | PPARgamma-independent antitumor effects of thiazolidinediones | Q37267184 |
| | Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies | Q38061184 |
| | Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. | Q40669494 |
| | Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death | Q41970353 |
| | PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro | Q42521446 |
| | A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. | Q42607754 |
| | Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. | Q43254579 |
| | Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels. | Q45926666 |
| | Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers | Q46422710 |
| | Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event | Q46599209 |
| | Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists | Q46882706 |
| | Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis | Q47613876 |
| | Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action. | Q53338744 |
| | Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus | Q59656664 |
| | Pioglitazone and bladder cancer | Q82248231 |
| P433 | issue | 9 | |
| P921 | main subject | bladder cancer | Q504775 |
| P304 | page(s) | 693-707 | |
| P577 | publication date | 2013-07-20 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? | |
| P478 | volume | 36 | |